The Trans-NIH Consortium aims to develop precision medicine approaches to improve treatment response to behavioral weight-loss interventions through the integration of new genetic discoveries. To achieve this goal, the National Institutes of Health invited investigators with existing large randomized controlled trials (RCTs) testing lifestyle interventions for weight loss among adults to join the Consortium. The existing RCTs have available biospecimens that are suitable for a large collaborative genome-wide study, using either genome-wide association study (GWAS) or next-generation sequencing study designs or platforms (e.g. Whole-genome sequencing), which aims to identify genetic variants associated with intentional weight loss. The Consortium plans to assess the feasibility of pooling RCTs to examine the well-established variability in weight loss treatment response and has the potential to improve treatment outcomes. As the next step in this process, the Trans-NIH Consortium is holding this special “town hall” style session to solicit your interest in participating in the consortium and to stimulate input and recommendations from the obesity research community.
Using Genomic Information to Guide Weight Loss Management
Molly S Bray, PhD
Rationale for Developing the Trans-NIH Consortium to Address Obesity Treatment
Tanya Agurs-Collins, PhD RD
Variability in Response to Weight Loss Intervention- PREDIMED-PLUS
Dolores Corella, PhD
Behavioral Change Taxonomy to Predict Obesity Treatment
Deborah F Tate, PhD; Steve H Belle, PhD MScHyg.
Panel Discussion / Q&A
Tanya Agurs-Collins, PhD RD; Steve H Belle, PhD MScHyg.